A research team has unveiled new insights into how weather influences the spread of dengue fever. The study identifies temperature and rainfall as critical factors driving the global surge in dengue ...

The NIH announced that it is launching a phase 2 human challenge trial of AV-1, an investigational monoclonal antibody to ...

The illness typically lasts two to seven days, but severe cases can be deadly. An affected person will have flu-like symptoms ...

Three species of mosquito are of particular concern in Europe, according to the European Centre for Disease Prevention and ...

Business debate on research and innovation (R&I) funding in the EU’s new mandate, global health leaders underlined the ...

The Pan American Health Organization (PAHO) has issued an epidemiological alert regarding the increased risk of dengue outbreaks in the Americas, attributed to the growing circulation of the DENV-3 ...

The trial will see healthy volunteers infected with dengue to test the impact of AbViro’s monoclonal antibody therapy.

Biological scientists have uncovered how the dengue virus uses its envelope protein to capture human plasmin from a blood meal to enhance the permeability of the mosquito midgut for infection.

A study was conducted to assess the safety and tolerability of the tetravalent live-attenuated dengue vaccine Qdenga®, which received marketing approval in Germany in 2022. The study evaluated vaccine ...

A clinical trial supported by the National Institutes of Health (NIH) is testing an experimental treatment designed to help ...

First chikungunya vaccine recommended by the CHMP for persons as young as 12 years old.The virus-like particle (VLP) single-dose chikungunya ...